Molecular imaging for monitoring treatment response in breast cancer patients

European Journal of Pharmacology

Volumn 717, Issue 1-3, 2013, Pages 2-11

  Bensch, Frederike ^a   Van Kruchten, Michel ^a   Lamberts, Laetitia E ^a   Schröder, Carolien P ^a   Hospers, Geke A P ^a   Brouwers, Adrienne H ^a   Van Vugt, Marcel A T M ^a   De Vries, Elisabeth G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Breast cancer; Molecular imaging; PET; RECIST; Response monitoring

Indexed keywords

ANDROGEN RECEPTOR; ANTHRACYCLINE; AROMATASE INHIBITOR; BEVACIZUMAB; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; FLUORODEOXYTHYMIDINE F18; FULVESTRANT; GEMCITABINE; GROWTH FACTOR RECEPTOR; HORMONE ANTAGONIST; LUMINESPIB; PROGESTERONE RECEPTOR; RADIOPHARMACEUTICAL AGENT; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; ZIRCONIUM; ZIRCONIUM 89;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTRAST ENHANCEMENT; DNA SYNTHESIS; DRUG RECEPTOR BINDING; DRUG UPTAKE; HUMAN; ISOTOPE LABELING; MAMMOGRAPHY; MOLECULAR IMAGING; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

BREAST CANCER; MOLECULAR IMAGING; PET; RECIST; RESPONSE MONITORING;

BREAST NEOPLASMS; HUMANS; MOLECULAR IMAGING; RECEPTORS, GROWTH FACTOR; RECEPTORS, STEROID; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84885960918     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.01.079     Document Type: Review

References (94)

1. E. Amir, N. Miller, W. Geddie, O. Freedman, F. Kassam, C. Simmons, M. Oldfield, G. Dranitsaris, G. Tomlinson, A. Laupacis, I.F. Tannock, and M. Clemons Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer J. Clin. Oncol. 30 2012 587 592
2. H.D. Bear, G. Tang, P. Rastogi, C.E. Geyer Jr, A. Robidoux, J.N. Atkins, L. Baez-Diaz, A.M. Brufsky, R.S. Mehta, L. Fehrenbacher, J.A. Young, F.M. Senecal, R. Gaur, R.G. Margolese, P.T. Adams, H.M. Gross, J.P. Costantino, S.M. Swain, E.P. Mamounas, and N. Wolmark Bevacizumab added to neoadjuvant chemotherapy for breast cancer N. Engl. J. Med. 366 2012 310 320
3. M. Bergstrom, A. Monazzam, P. Razifar, S. Ide, R. Josephsson, and B. Langstrom Modeling spheroid growth, PET tracer uptake, and treatment effects of the Hsp90 inhibitor NVP-AUY922 J. Nucl. Med. 49 2008 1204 1210 (Pubitemid 351948032)
4. 18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy J. Clin. Oncol. 24 2006 3026 3031 (Pubitemid 46638936)
5. F. Cardoso, E. Senkus-Konefka, L. Fallowfield, A. Costa, M. Castiglione ESMO Guidelines Working Group Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann. Oncol. 21 Suppl 5 2010 v15 9
6. 18F-fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis. Eur. J. Cancer [Epub ahead of print].
7. L.C. Collins, K.S. Cole, J.D. Marotti, R. Hu, S.J. Schnitt, and R.M. Tamimi Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study Mod. Pathol. 24 2011 924 931
8. 18F]-3′'Deoxy-3′-fluorothymidine positron emission tomography and breast cancer response to docetaxel Clin. Cancer Res. 17 2011 7664 7672
9. 18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer Clin. Cancer Res. 12 2006 6437 6443 (Pubitemid 44799716)
10. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer J. Nucl. Med. 51 2010 1213 1218
11. 18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer J. Clin. Oncol. 27 2009 3303 3311
12. 18F-fluoro- 16alpha,17alpha-[(R)-(1′-alpha-furylmethylidene)dioxy]-19-norpregn- 4-ene-3,20-dione J. Nucl. Med. 53 2012 363 370
13. F. Dehdashti, J.E. Mortimer, K. Trinkaus, M.J. Naughton, M. Ellis, J.A. Katzenellenbogen, M.J. Welch, and B.A. Siegel PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer Breast Cancer Res. Treat. 113 2009 509 517
14. F. Dehdashti, J. Picus, J.M. Michalski, C.S. Dence, B.A. Siegel, J.A. Katzenellenbogen, and M.J. Welch Positron tomographic assessment of androgen receptors in prostatic carcinoma Eur. J. Nucl. Med. Mol. Imaging 32 2005 344 350 (Pubitemid 40562127)
15. F. Dehdashti, F.L. Flanagan, J.E. Mortimer, J.A. Katzenellenbogen, M.J. Welch, and B.A. Siegel Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy Eur. J. Nucl. Med. 26 1999 51 56 (Pubitemid 29137739)
16. F. Dehdashti, J.E. Mortimer, B.A. Siegel, L.K. Griffeth, T.J. Bonasera, M.J. Fusselman, D.D. Detert, P.D. Cutler, J.A. Katzenellenbogen, and M.J. Welch Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays J. Nucl. Med. 36 1995 1766 1774
17. 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer Clin. Pharmacol. Ther. 87 2010 586 592
18. E.C. Dijkers, J.G. Kosterink, A.P. Rademaker, L.R. Perk, G.A. van Dongen, J. Bart, J.R. de Jong, E.G. de Vries, and M.N. Lub-de Hooge Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging J. Nucl. Med. 50 2009 974 981
19. 18F-FDG PET J. Nucl. Med. 46 2005 1144 1150 (Pubitemid 43741076)
20. H.F. Dvorak Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy J. Clin. Oncol 20 2002 4368 4380 (Pubitemid 35266299)
21. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) C. Davies, J. Godwin, R. Gray, M. Clarke, D. Cutter, S. Darby, P. McGale, H.C. Pan, C. Taylor, Y.C. Wang, M. Dowsett, J. Ingle, and R. Peto Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet 378 2011 771 784
22. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, and J. Verweij New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur. J. Cancer 45 2009 228 247
23. A.D. Elias, D.R. Cochrane, B.M. Jacobsen, D.M. Cittelly, E.N. Howe, A. Jean, N.S. Spoelstra, A.A. Protter, and J.K. Richer Effect of MDV3100, an androgen receptor signaling inhibitor, on tumor growth of estrogen and androgen receptor-positive (ER+/AR+) breast cancer xenografts J. Clin. Oncol. 2012 30 (suppl; abstr 564)
24. A.D. Elias, J.K. Richer, P. LoRusso, A.C. Peterson, J.L. Steinberg, J. Mordenti, C. Lopez, C. Hudis, and T.A. Traina MDV3100-08: A phase I open-label, dose-escalation study evaluating the safety, tolerability, and pharmacokinetics of MDV3100 in women with incurable breast cancer J. Clin. Oncol. 2012 30 (suppl; abstr TPS668)
25. M.J. Ellis, F. Gao, F. Dehdashti, D.B. Jeffe, P.K. Marcom, L.A. Carey, M.N. Dickler, P. Silverman, G.F. Fleming, A. Kommareddy, S. Jamalabadi-Majidi, R. Crowder, and B.A. Siegel Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study JAMA 302 2009 774 780
26. N. Ferrara Vascular endothelial growth factor: basic science and clinical progress Endocr. Rev. 25 2004 581 611 (Pubitemid 39099316)
27. A.M. Fowler, S.R. Chan, T.L. Sharp, N.M. Fettig, D. Zhou, C.S. Dence, K.E. Carlson, M. Jeyakumar, J.A. Katzenellenbogen, R.D. Schreiber, and M.J. Welch Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer J. Nucl. Med. 53 2012 1119 1126
28. 18F-FDG PET studies in mice J. Nucl. Med. 47 2006 999 1006 (Pubitemid 46939953)
29. 89Zr-Bevacizumab PET imaging in primary breast cancer Ann. Oncol. 23 suppl 2 2012
30. S.B. Gaykema, A.H. Brouwers, S. Hovenga, M.N. Lub-de Hooge, E.G. De Vries, and C.P. Schroder Zirconium-89-trastuzumab positron emission tomography as a tool to solve a clinical dilemma in a patient with breast cancer J. Clin. Oncol. 30 2012 e74 5
31. A. Gennari, A. Piccardo, V. Altrinetti, D. Corradengo, G. Villavecchia, and A. De Censi Whither the PET scan? The role of PET imaging in the staging and treatment of breast cancer Curr. Oncol. Rep. 14 2012 20 26
32. 18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients Clin. Breast Cancer. 1 2000 156 161
33. A. Gucalp, S.M. Tolaney, S.J. Isakoff, J.N. Ingle, M.C. Liu, L.A. Carey, K.L. Blackwell, H.S. Rugo, L. Nabell, A. Forero-Torres, V. Stearns, L. Momen, J. Gonzalez, G.D. Giri, S. Patil, K. Feigin, C. Hudis, and T.A. Traina Targeting the androgen receptor (AR) in women with AR+ ER-/PR- metastatic breast cancer (MBC) J. Clin. Oncol. 2012 30 (suppl; abstr 1006)
34. T. Hamaoka, C.M. Costelloe, J.E. Madewell, P. Liu, D.A. Berry, R. Islam, R.L. Theriault, G.N. Hortobagyi, and N.T. Ueno Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer Br. J. Cancer 102 2010 651 657
35. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
36. T. Jansson, J.E. Westlin, H. Ahlstrom, A. Lilja, B. Langstrom, and J. Bergh Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J. Clin. Oncol. 13 1995 1470 1477
37. K. Kawada, K. Murakami, T. Sato, Y. Kojima, H. Ebi, H. Mukai, M. Tahara, K. Shimokata, and H. Minami Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors Jpn. J. Clin. Oncol. 37 2007 44 48 (Pubitemid 47090722)
38. 18F]fluorothymidine positron emission tomography Eur. J. Nucl. Med. Mol. Imaging 34 2007 1339 1347 (Pubitemid 47312585)
39. 18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography Clin. Cancer Res. 15 2009 6649 6657
40. 18F-FDG in patients with progressive, metastatic prostate cancer J. Nucl. Med. 45 2004 366 373 (Pubitemid 47618608)
41. S.J. Lee, S.Y. Kim, J.H. Chung, S.J. Oh, J.S. Ryu, Y.S. Hong, T.W. Kim, and D.H. Moon Induction of thymidine kinase 1 after 5-fluorouracil as a mechanism for 3′-deoxy-3′-[18F]fluorothymidine flare Biochem. Pharmacol. 80 2010 1528 1536
42. H.S. Lim, W. Yoon, T.W. Chung, J.K. Kim, J.G. Park, H.K. Kang, H.S. Bom, and J.H. Yoon FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitations Radiographics 27 Suppl 1 2007 S197 213
43. H.M. Linden, B.F. Kurland, L.M. Peterson, E.K. Schubert, J.R. Gralow, J.M. Specht, G.K. Ellis, T.J. Lawton, R.B. Livingston, P.H. Petra, J.M. Link, K.A. Krohn, and D.A. Mankoff Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer Clin. Cancer Res. 17 2011 4799 4805
44. H.M. Linden, S.A. Stekhova, J.M. Link, J.R. Gralow, R.B. Livingston, G.K. Ellis, P.H. Petra, L.M. Peterson, E.K. Schubert, L.K. Dunnwald, K.A. Krohn, and D.A. Mankoff Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer J. Clin. Oncol. 24 2006 2793 2799 (Pubitemid 46630578)
45. J.R. Mackey, R.S. Kerbel, K.A. Gelmon, D.M. McLeod, S.K. Chia, D. Rayson, S. Verma, L.L. Collins, A.H. Paterson, A. Robidoux, and K.I. Pritchard Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials Cancer Treat. Rev. 38 2012 673 688
46. G. Mariani, A. Gennari, A. Giorgetti, S. Donati, G. Puccini, N. Nista, D. Dani, C. Bengala, P.F. Conte, and P.A. Salvadori Early assessment by PET with FDG of response to first-line chemotherapy of metastatic breast cancer Clin. Positron Imaging 2 1999 342
47. 18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice J. Nucl. Med. 50 2009 1848 1856
48. M.A. Mintun, M.J. Welch, B.A. Siegel, C.J. Mathias, J.W. Brodack, A.H. McGuire, and J.A. Katzenellenbogen Breast cancer: PET imaging of estrogen receptors Radiology 169 1988 45 48
49. M.M. Moasser The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis Oncogene 26 2007 6469 6487 (Pubitemid 47530601)
50. A. Monazzam, P. Razifar, S. Ide, M. Rugaard Jensen, R. Josephsson, C. Blomqvist, B. Langstrom, and M. Bergstrom Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake Nucl. Med. Biol. 36 2009 335 342
51. N. Mortazavi-Jehanno, A.L. Giraudet, L. Champion, F. Lerebours, E. Le Stanc, V. Edeline, O. Madar, D. Bellet, A.P. Pecking, and J.L. Alberini Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study Eur. J. Nucl. Med. Mol. Imaging 39 2012 450 460
52. J.E. Mortimer, F. Dehdashti, B.A. Siegel, K. Trinkaus, J.A. Katzenellenbogen, and M.J. Welch Metabolic flare: indicator of hormone responsiveness in advanced breast cancer J. Clin. Oncol. 19 2001 2797 2803 (Pubitemid 32538187)
53. 18F]fluoro- 17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy Clin. Cancer Res 2 1996 933 939
54. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922 J. Nucl. Med. 51 2010 761 767
55. W.B. Nagengast, E.G. de Vries, G.A. Hospers, N.H. Mulder, J.R. de Jong, H. Hollema, A.H. Brouwers, G.A. van Dongen, L.R. Perk, and M.N. Lub-de Hooge In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft J. Nucl. Med. 48 2007 1313 1319 (Pubitemid 47242797)
56. National Comprehensive Cancer Network (NCCN), 2012. NCCN clinical practice guidelines in oncology (NCCN guidelines); Breast Cancer version I.2012. 2012.
57. N. Niikura, J. Liu, N. Hayashi, S.L. Palla, Y. Tokuda, G.N. Hortobagyi, N.T. Ueno, and R.L. Theriault Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases Cancer 118 2012 2039 2047
58. Y. Ogawa, E. Hai, K. Matsumoto, K. Ikeda, S. Tokunaga, H. Nagahara, K. Sakurai, T. Inoue, and Y. Nishiguchi Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers Int. J. Clin. Oncol. 13 2008 431 435
59. S. Oliveira, G.A. van Dongen, M. Stigter-van Walsum, R.C. Roovers, J.C. Stam, W. Mali, P.J. van Diest, and P.M. van Bergen en Henegouwen Rapid visualisation of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody Mol. Imaging. 11 2012 33 46
60. 89Zr-bevacizumab PET imaging in metastatic renal cell carcinoma patients before and during antiangiogenic treatment J. Clin. Oncol. 2012 30 (suppl; abstr 10581)
61. T.H. Oude Munnink, E.C. Dijkers, S.J. Netters, M.N. Lub-de Hooge, A.H. Brouwers, J.G. Haasjes, C.P. Schroder, and E.G. de Vries Trastuzumab pharmacokinetics influenced by extent human epidermal growth factor receptor 2-positive tumor load J. Clin. Oncol. 28 2010 e355 356
62. T.H. Oude Munnink, W.B. Nagengast, A.H. Brouwers, C.P. Schroder, G.A. Hospers, M.N. Lub-de Hooge, E. van der Wall, P.J. van Diest, and E.G. de Vries Molecular imaging of breast cancer Breast 18 suppl 3 2009 S66 73
63. P.J. Perik, M.N. Lub-De Hooge, J.A. Gietema, W.T. van der Graaf, M.A. de Korte, S. Jonkman, J.G. Kosterink, D.J. van Veldhuisen, D.T. Sleijfer, P.L. Jager, and E.G. de Vries Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer J. Clin. Oncol. 24 2006 2276 2282 (Pubitemid 46630657)
64. 18F- fluoroestradiol J. Nucl. Med. 49 2008 367 374 (Pubitemid 351355201)
65. B.S. Pio, C.K. Park, R. Pietras, W.A. Hsueh, N. Satyamurthy, M.D. Pegram, J. Czernin, M.E. Phelps, and D.H. Silverman Usefulness of 3′-[F-18] fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy Mol. Imaging Biol. 8 2006 36 42 (Pubitemid 44201576)
66. E.L. Rosen, W.B. Eubank, and D.A. Mankoff FDG PET, PET/CT, and breast cancer imaging Radiographics 27 Suppl 1 2007 S215 29
67. J.S. Ross, E.A. Slodkowska, W.F. Symmans, L. Pusztai, P.M. Ravdin, and G.N. Hortobagyi The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine Oncologist 14 2009 320 368
68. D.M. Sataloff, B.A. Mason, A.J. Prestipino, U.L. Seinige, C.P. Lieber, and Z. Baloch Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome J. Am. Coll. Surg 180 1995 297 306
69. H.I. Scher, T.M. Beer, C.S. Higano, A. Anand, M.E. Taplin, E. Efstathiou, D. Rathkopf, J. Shelkey, E.Y. Yu, J. Alumkal, D. Hung, M. Hirmand, L. Seely, M.J. Morris, D.C. Danila, J. Humm, S. Larson, M. Fleisher, C.L. Sawyers Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study Lancet 375 2010 1437 1446
70. L.E. Schnipper, T.J. Smith, D. Raghavan, D.W. Blayney, P.A. Ganz, T.M. Mulvey, and D.S. Wollins American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology J. Clin. Oncol. 30 2012 1715 1724
71. C.P. Schroder, J.V. Pedersen, S. Chua, C. Swanton, M. Akimov, S. Ide, C. Fernandez-Ibarra, A. Dzik-Jurasz, E. De Vries, S.B. Gaykema, and U. Banerji Use of biomarkers and imaging to evaluate the treatment effect of AUY922, an HSP90 inhibitor, in patients with HER2+ or ER+ metastatic breast cancer ASCO Meet. Abstr. 29 2011 e11024
72. C. Shah, T.W. Miller, S.K. Wyatt, E.T. McKinley, M.G. Olivares, V. Sanchez, D.D. Nolting, J.R. Buck, P. Zhao, M.S. Ansari, R.M. Baldwin, J.C. Gore, R. Schiff, C.L. Arteaga, and H.C. Manning Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer Clin. Cancer Res. 15 2009 4712 4721
73. H. Sihto, J. Lundin, M. Lundin, T. Lehtimaki, A. Ristimaki, K. Holli, L. Sailas, V. Kataja, T. Turpeenniemi-Hujanen, J. Isola, P. Heikkila, and H. Joensuu Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study Breast Cancer Res. 13 2011 R87
74. C. Simmons, N. Miller, W. Geddie, D. Gianfelice, M. Oldfield, G. Dranitsaris, and M.J. Clemons Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann. Oncol. 20 2009 1499 1504
75. D. Slamon, W. Eiermann, N. Robert, T. Pienkowski, M. Martin, M. Press, J. Mackey, J. Glaspy, A. Chan, M. Pawlicki, T. Pinter, V. Valero, M.C. Liu, G. Sauter, G. von Minckwitz, F. Visco, V. Bee, M. Buyse, B. Bendahmane, I. Tabah-Fisch, M.A. Lindsay, A. Riva, J. Crown Breast Cancer International Research Group Adjuvant trastuzumab in HER2-positive breast cancer N. Engl. J. Med. 365 2011 1273 1283
76. D.J. Slamon, W. Godolphin, L.A. Jones, J.A. Holt, S.G. Wong, D.E. Keith, W.J. Levin, S.G. Stuart, J. Udove, and A. Ullrich Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712 (Pubitemid 19147683)
77. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182 (Pubitemid 17231334)
78. 18F-FDG PET J. Nucl. Med. 47 2006 793 796 (Pubitemid 46768442)
79. P.M. Smith-Jones, D.B. Solit, T. Akhurst, F. Afroze, N. Rosen, and S.M. Larson Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors Nat. Biotechnol. 22 2004 701 706 (Pubitemid 38702826)
80. C.E. Stevenson, M. Nagahashi, S. Ramachandran, A. Yamada, H.D. Bear, and K. Takabe Bevacizumab and breast cancer: what does the future hold? Future Oncol 8 2012 403 414
81. 64Cu-DOTA-trastuzumab-PET imaging in patients with HER2-positive breast cancer J. Clin. Oncol. 2012 30 (suppl; abstr 10519)
82. U. Tateishi, C. Gamez, S. Dawood, H.W. Yeung, M. Cristofanilli, and H.A. Macapinlac Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT Radiology 247 2008 189 196
83. A.G. Terwisscha van Scheltinga, G.M. van Dam, W.B. Nagengast, V. Ntziachristos, H. Hollema, J.L. Herek, C.P. Schroder, J.G. Kosterink, M.N. Lub-de Hoog, and E.G. de Vries Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies J. Nucl. Med. 52 2011 1778 1785
84. S. Ueda, H. Tsuda, T. Saeki, J. Omata, A. Osaki, T. Shigekawa, J. Ishida, K. Tamura, Y. Abe, T. Moriya, and J. Yamamoto Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study Breast Cancer 18 2011 299 308
85. M. van Kruchten, A.W. Glaudemans, E.F. de Vries, R.G. Beets-Tan, C.P. Schroder, R.A. Dierckx, E.G. de Vries, and G.A. Hospers PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma J. Nucl. Med. 53 2012 182 190
86. 18F-FDG for differentiating tumor from inflammation in a rodent model J. Nucl. Med. 45 2004 695 700 (Pubitemid 47618601)
87. S. Verma, D. Miles, L. Gianni, I.E. Krop, M. Welslau, J. Baselga, M. Pegram, D.Y. Oh, V. Dieras, E. Guardino, L. Fang, M.W. Lu, S. Olsen, K. Blackwell EMILIA Study Group Trastuzumab emtansine for HER2-positivve advanced breast cancer N. Engl. J. Med. 19 2012 1783 1791
88. C.L. Vogel, M.A. Cobleigh, D. Tripathy, J.C. Gutheil, L.N. Harris, L. Fehrenbacher, D.J. Slamon, M. Murphy, W.F. Novotny, M. Burchmore, S. Shak, S.J. Stewart, and M. Press Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J. Clin. Oncol. 20 2002 719 726 (Pubitemid 34111379)
89. G. von Minckwitz, H. Eidtmann, M. Rezai, P.A. Fasching, H. Tesch, H. Eggemann, I. Schrader, K. Kittel, C. Hanusch, R. Kreienberg, C. Solbach, B. Gerber, C. Jackisch, G. Kunz, J.U. Blohmer, J. Huober, M. Hauschild, T. Fehm, B.M. Muller, C. Denkert, S. Loibl, V. Nekljudova, M. Untch German Breast Group Arbeitsgemeinschaft Gynakologische Onkologie-Breast Study Groups Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer N. Engl. J. Med. 366 2012 299 309
90. E.G. de Vries, T.H. Oude Munnink, M.A. van Vugt, and W.B. Nagengast Toward molecular imaging-driven drug development in oncology Cancer. Discov 1 2011 25 28
91. G. von Minckwitz, H. Eidtmann, S. Loibl, J.U. Blohmer, S.D. Costa, P.A. Fasching, R. Kreienberg, J. Hilfrich, B. Gerber, C. Hanusch, T. Fehm, D. Strumberg, C. Solbach, V. Nekljudova, M. Untch German Breast Group and Arbeitsgemeinschaft Gynakologische Onkologie-Brust investigators Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial Ann. Oncol. 22 2011 301 306
92. R.L. Wahl, H. Jacene, Y. Kasamon, and M.A. Lodge From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors J. Nucl. Med. 50 Suppl 1 2009 122S-50S
93. 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis Breast Cancer Res. Treat 131 2012 357 369
94. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur. J. Cancer 35 1999 1773 1782 (Pubitemid 29512308)